Innovation for a Purpose
"When you can not breathe, nothing else matters"
Developing innovative best-in-class therapies to help patients with obstructive airway diseases breathe easily.
CILA Therapeutics is developing a proprietary, first-in-class dry powder microsphere for the treatment of obstructive airway diseases
Persistent Airway Plugs: A Call for Clinical Recognition and Novel Therapies
At CILA, we are working to create a future where patients with obstructive airway diseases have access to an effective therapy to improve and maintain normal airway function, protect the integrity of the lung and prevent ongoing and long-term lung damage.
Currently, there are no effective therapies for the treatment of mucus plugs that make breathing difficult and prevent other inhaled therapies from reaching their target and being effective. CILA is committed to developing therapies to clear mucus obstruction.
News
CILA Therapeutics CEO Safia Rizvi has been named to the prestigious 2024 50 Women to Watch for Boards list
BOSTON June 28, 2024 — CILA Therapeutics CEO Safia Rizvi has been named to the prestigious 2024 50 Women to Watch for Corporate Boards list, by 50/50 Women on Boards. Rizvi is a visionary biopharmaceutical business executive and scientist, who has dedicated her career to discovering and commercializing treatments that improve people’s lives across the globe. Rizvi and the other finalists are recognized as board-ready executives, who can make an immediate positive impact.
CILA CEO selected as 2023 Termeer Foundation Fellow
BOSTON, April 10, 2023 — The Termeer Foundation is proud to announce the Class of 2023 Termeer Fellows. The Class of 2023 include Safia Rizvi, CILA Therapeutics; and 19 other outstanding entrepreneurs.
CILA to present at Align Summit
CILA Therapeutics was selected to present at the @MassBio Align Summit w/ insights by @McKinsey. The day will include keynotes, panel discussions, and pitches from other innovative seed/series A Biotech and MedTech start-ups.
Collaborators
